A 29-year-old lady receiving repeated blood transfusions for β thalassemia since childhood, presented with rapidly deteriorating symptoms of night blindness and peripheral visual field loss. She was recently commenced on high-dose intravenous desferrioxamine for reducing the systemic iron overload. Clinical and investigative findings were consistent with desferrioxamine-related pigmentary retinopathy and optic neuropathy. Recovery was partial following cessation of desferrioxamine. This report highlights the ocular side-effects of desferrioxamine mesylate and the need to be vigilant in patients on high doses of desferrioxamine.Sumu Simon, Paul A Athanasiov, Rajeev Jain, Grant Raymond, Jagjit S Gilhotr
Abstract Background Deferoxamine (DFO) is one of the most commonly used chelation treatments for tra...
Neurophysiologic investigations were performed in 34 Chinese patients with β-thalassemia ma...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
SUMMARY Three patients with rheumatoid disease were given the 'iron chelating ' drug desfe...
WOS: 000360662000025Thalassemias are a heterogeneous group of autosomal recessive diseases character...
Seven patients with rheumatoid disease were given the iron-chelating drug desferrioxamine (DFX) to e...
Objective: To determine the incidences of ocular toxicity and ocular findings, including structural ...
PURPOSE: Deferoxamine (DFO) is a chelating agent used widely for the treatment of transfusional hemo...
Transfusion dependent thalassemia is a hematological condition characterized by imbalance in synthes...
Purpose: To study the ocular manifestations in multiple transfused beta-thalassemia major patients ...
Introduction: The current article mainly attempts to evaluate the incidences of ocular toxicity and ...
Deferoxamine mesylate (DFO) is the most commonly used iron-chelating agent to treat transfusion-rela...
Neurophysiologic investigations were performed in 34 Chinese patients with β-thalassemia major maint...
PubMed ID: 17093379Thalassaemia major is a severe chronic hemolytic disease, resulted with iron over...
A 54-year-old female patient had a history of end-stage renal disease (ESRD) under continuous automa...
Abstract Background Deferoxamine (DFO) is one of the most commonly used chelation treatments for tra...
Neurophysiologic investigations were performed in 34 Chinese patients with β-thalassemia ma...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
SUMMARY Three patients with rheumatoid disease were given the 'iron chelating ' drug desfe...
WOS: 000360662000025Thalassemias are a heterogeneous group of autosomal recessive diseases character...
Seven patients with rheumatoid disease were given the iron-chelating drug desferrioxamine (DFX) to e...
Objective: To determine the incidences of ocular toxicity and ocular findings, including structural ...
PURPOSE: Deferoxamine (DFO) is a chelating agent used widely for the treatment of transfusional hemo...
Transfusion dependent thalassemia is a hematological condition characterized by imbalance in synthes...
Purpose: To study the ocular manifestations in multiple transfused beta-thalassemia major patients ...
Introduction: The current article mainly attempts to evaluate the incidences of ocular toxicity and ...
Deferoxamine mesylate (DFO) is the most commonly used iron-chelating agent to treat transfusion-rela...
Neurophysiologic investigations were performed in 34 Chinese patients with β-thalassemia major maint...
PubMed ID: 17093379Thalassaemia major is a severe chronic hemolytic disease, resulted with iron over...
A 54-year-old female patient had a history of end-stage renal disease (ESRD) under continuous automa...
Abstract Background Deferoxamine (DFO) is one of the most commonly used chelation treatments for tra...
Neurophysiologic investigations were performed in 34 Chinese patients with β-thalassemia ma...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...